Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Barata

Showing results (191-200 of 203) with videos related to

Pageof 21
Sort By:
The Oncologist|December 30, 2025
EXTRA-PC: A phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancerAlbert Jang, Peggy Fowler, Kathryn Helminiak, et al.
European Urology Oncology|December 21, 2024
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study DataTanya Jindal, Cindy Jiang, Omar Alhalabi, et al.
The Oncologist|June 19, 2025
REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimensJeffrey Zhong, Albert Jang, Bashar Abuqayas, et al.
JCO Precision Oncology|April 5, 2024
Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable AlterationsJoseph J Park, Alec Chu, Jinju Li, et al.
Nature Communications|December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerSoumyajit Roy, Yilun Sun, Maha Hussain, et al.
Cancer|December 9, 2021
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) studyVadim S Koshkin, Nicholas Henderson, Marihella James, et al.
The Oncologist|October 7, 2025
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative studyCindy Y Jiang, Hyunsoo Hwang, Ilana Y Epstein, et al.
JAMA Network Open|January 16, 2026
Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate CancerPedro C Barata, June K Corrigan, Jennifer La, et al.
Clinical Genitourinary Cancer|February 5, 2026
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE DatabaseAlbert Jang, Tanya Jindal, Ali Raza Khaki, et al.
The Oncologist|August 13, 2022
Supporting Patients with Cancer after Dobbs v. Jackson Women's Health OrganizationAndrew G Shuman, Matti S Aapro, Benjamin Anderson, et al.
Pageof 21

Showing results (191-200 of 203) with videos related to

Sort By:
Pageof 21
The Oncologist|December 30, 2025
EXTRA-PC: A phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancerAlbert Jang, Peggy Fowler, Kathryn Helminiak, et al.
European Urology Oncology|December 21, 2024
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study DataTanya Jindal, Cindy Jiang, Omar Alhalabi, et al.
The Oncologist|June 19, 2025
REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimensJeffrey Zhong, Albert Jang, Bashar Abuqayas, et al.
JCO Precision Oncology|April 5, 2024
Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable AlterationsJoseph J Park, Alec Chu, Jinju Li, et al.
Nature Communications|December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerSoumyajit Roy, Yilun Sun, Maha Hussain, et al.
Cancer|December 9, 2021
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) studyVadim S Koshkin, Nicholas Henderson, Marihella James, et al.
The Oncologist|October 7, 2025
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative studyCindy Y Jiang, Hyunsoo Hwang, Ilana Y Epstein, et al.
JAMA Network Open|January 16, 2026
Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate CancerPedro C Barata, June K Corrigan, Jennifer La, et al.
Clinical Genitourinary Cancer|February 5, 2026
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE DatabaseAlbert Jang, Tanya Jindal, Ali Raza Khaki, et al.
The Oncologist|August 13, 2022
Supporting Patients with Cancer after Dobbs v. Jackson Women's Health OrganizationAndrew G Shuman, Matti S Aapro, Benjamin Anderson, et al.
Pageof 21